Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Children's Hospital of Eastern Ontario | OTHER |
| Ottawa Hospital Research Institute | OTHER |
| Mount Sinai Hospital, Canada | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Spartan FRX CYP2C19 Test System (hereafter referred to as the 'FRX System') is a qualitative in vitro diagnostic test for the identification of a patient's CYP2C19 *2, *3 and *17 genotypes from genomic DNA obtained from buccal swab samples. The objective of the study is to evaluate the performance of the FRX System under multivariate conditions including different days, sites, operators and systems.
The FRX system is comprised of hardware and consumable components. The hardware components of the system include an Analyzer (thermal cycler with fluorescence detection capability), a notebook computer and a printer. The consumable component of the FRX system is a sample collection kit. Each kit contains a buccal swab (used to collect the patient sample) and a tube containing the reagents required for genomic DNA extraction and PCR (polymerase chain reaction) amplification stages of the test.
The Spartan FRX System is capable of detecting three CYP2C19 SNPs(single nucleotide polymorphism) (*2, *3, *17) in each test performed. An individual sample collection kit is required for each SNP tested; therefore three sample collection kits are required for each test performed on the system.
To perform a test, the user collects three buccal samples from the patient and then inserts a sample into each of the three reagent tubes (one for each of the CYP2C19 loci *2, *3 and *17). The reagent tubes are placed into the Analyzer and the FRX system automates the processes of DNA extraction, PCR amplification, fluorescent signal detection and data analysis. The system provides the user with a printed result listing the patient genotypes at the *2, *3 and *17 loci.
The objective of the study is to evaluate the performance of the FRX System under multivariate conditions. Specifically, the following variables will be included in the study:
Test performance is defined as the number of correct genotype calls, expressed as a percentage of the total number of tests performed on the system.
For both the first-pass and second-pass results, 1-sided 95% confidence lower limits will be calculated using the score method for the % correct calls (i.e. % agreement).
Genotype results from the FRX system will be compared with results of DNA sequencing. The result of the FRX System test will be determined to be correct if the genotype calls for all three SNPs are identical to the genotypes determined by DNA sequencing for that sample/individual.
Results of the Reproducibility Study will be acceptable if the lower bound of a 1-sided 95% confidence limit of the total correct call rate per genotype is greater than or equal to 95%, based on second-pass results.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Spartan FRX CYP2C19 Test System | Device |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System. | Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system. All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement). | After second pass result is complete (~3h) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
8 Individuals with predetermined CYP2C19 *2,*3 and *17 genotypes
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chris JE Harder, PhD | Spartan Bioscience | Principal Investigator |
| Azar Azad, PhD | MOUNT SINAI HOSPITAL | Principal Investigator |
| Marc Desjardins, PhD | Ottawa Hosptial Research Institute | Principal Investigator |
| Jean McGowan-Jordan, PhD | Children's Hospital of Eastern Ontario | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital of Eastern Ontario | Ottawa | Ontario | K1H 8L6 | Canada | ||
| Ottawa Hospital Research Institute |
Spartan Bioscience
A total of 8 individuals were recruited for a company pool of known suspected genotypes; each with a different CYP2C19 genotype confirmed prior to the study by bi-directional sequencing.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | *1/*1 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG001 | *1/*2 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG002 | *2/*2 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG003 | *3/*1 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG004 | *1/*17 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG005 | *17/*17 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG006 | *2/*3 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| FG007 | *2/*17 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | *1/*1 CYP2C19 Genotype | |
| BG001 | *1/*2 CYP2C19 Genotype | |
| BG002 | *2/*2 CYP2C19 Genotype |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System. | Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system. All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement). | Posted | Number | 95% Confidence Interval | Percentage of Correct Calls | After second pass result is complete (~3h) | CYP2C19 Genotype | Participants |
|
Adverse events were monitored for the full duration of the trial (~2 months).
No adverse events were encountered.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | *1/*1 CYP2C19 Genotype |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Chris Harder | Spartan Bioscience Inc. | 613-228-7756 | 778 | chris.harder@spartanbio.com |
Not provided
Not provided
Not provided
Not provided
Not provided
| Ottawa |
| Ontario |
| K1H 8L6 |
| Canada |
| Mount Sinai Services | Toronto | Ontario | M5G 1Z5 | Canada |
| BG003 | *3/*1 CYP2C19 Genotype |
| BG004 | *1/*17 CYP2C19 Genotype |
| BG005 | *17/*17 CYP2C19 Genotype |
| BG006 | *2/*3 CYP2C19 Genotype |
| BG007 | *2/*17 CYP2C19 Genotype |
| BG008 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| *1/*1 CYP2C19 Genotype |
Subject had genotype confirmed via bi-directional sequencing. |
| OG001 | *1/*2 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| OG002 | *2/*2 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| OG003 | *3/*1 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| OG004 | *1/*17 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| OG005 | *17/*17 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| OG006 | *2/*3 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
| OG007 | *2/*17 CYP2C19 Genotype | Subject had genotype confirmed via bi-directional sequencing. |
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | *1/*2 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
| EG002 | *2/*2 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
| EG003 | *3/*1 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
| EG004 | *1/*17 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
| EG005 | *17/*17 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
| EG006 | *2/*3 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
| EG007 | *2/*17 CYP2C19 Genotype | 0 | 0 | 0 | 0 |
Not provided